Cortistatin-8, a synthetic cortistatin-derived ghrelin receptor ligand, does not modify the endocrine responses to acylated ghrelin or hexarelin in humans.

Prodam F, Benso A, Gramaglia E, Lucatello B, Riganti F, van der Lely AJ, Deghenghi R, Muccioli G, Ghigo E, Broglio F

Neuropeptides3 Dec 2007Cited by 4 (Europe PMC)

PMID18061663DOI10.1016/j.npep.2007.09.006PepBankPUB-18061663

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

4 results from studies that gave the peptide. 4 results from people.

01HumanNon-randomized trialEfficacy outcome
In 6 normal volunteers, a hexarelin bolus of 1.0 microg/kg i.v. stimulated GH secretion (p<0.05).
In plain wordsIn 6 healthy volunteers, hexarelin given into a vein raised growth hormone release compared with saline.
Peptide
Hexarelin
Outcome
IncreaseGH secretion after hexarelin
Study
n = 6
Comparator
Saline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1.0 microg/kg · intravenousAs given in this study (human).
Source sentences
Summary
As expected, both ghrelin and hexarelin stimulated GH, PRL, ACTH and cortisol secretion (p<0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
We studied the effects of CST-8 (2.0 microg/kg i.v. as a bolus or 2.0 microg/kg/h i.v. as infusion) on both spontaneous and ghrelin- or hexarelin- (1.0 microg/kg i.v. as bolus) stimulated GH, PRL, ACTH and cortisol secretion in 6 normal volunteers.
Report a problemFND-1806166301
02HumanNon-randomized trialEfficacy outcome
In 6 normal volunteers, a hexarelin bolus of 1.0 microg/kg i.v. stimulated PRL secretion (p<0.05).
In plain wordsIn 6 healthy volunteers, hexarelin given into a vein raised prolactin release compared with saline.
Peptide
Hexarelin
Outcome
IncreaseProlactin secretion after hexarelin
Study
n = 6
Comparator
Saline
Outcome group
Pituitary hormones · Endocrine and hormones
Studied dose
1.0 microg/kg · intravenousAs given in this study (human).
Source sentences
Summary
As expected, both ghrelin and hexarelin stimulated GH, PRL, ACTH and cortisol secretion (p<0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
We studied the effects of CST-8 (2.0 microg/kg i.v. as a bolus or 2.0 microg/kg/h i.v. as infusion) on both spontaneous and ghrelin- or hexarelin- (1.0 microg/kg i.v. as bolus) stimulated GH, PRL, ACTH and cortisol secretion in 6 normal volunteers.
Report a problemFND-1806166302
03HumanNon-randomized trialEfficacy outcome
In 6 normal volunteers, a hexarelin bolus of 1.0 microg/kg i.v. stimulated ACTH secretion (p<0.05).
In plain wordsIn 6 healthy volunteers, hexarelin given into a vein raised ACTH release compared with saline.
Peptide
Hexarelin
Outcome
IncreaseACTH secretion after hexarelin
Study
n = 6
Comparator
Saline
Outcome group
Stress hormones · Endocrine and hormones
Studied dose
1.0 microg/kg · intravenousAs given in this study (human).
Source sentences
Summary
As expected, both ghrelin and hexarelin stimulated GH, PRL, ACTH and cortisol secretion (p<0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
We studied the effects of CST-8 (2.0 microg/kg i.v. as a bolus or 2.0 microg/kg/h i.v. as infusion) on both spontaneous and ghrelin- or hexarelin- (1.0 microg/kg i.v. as bolus) stimulated GH, PRL, ACTH and cortisol secretion in 6 normal volunteers.
Report a problemFND-1806166303
04HumanNon-randomized trialEfficacy outcome
In 6 normal volunteers, a hexarelin bolus of 1.0 microg/kg i.v. stimulated cortisol secretion (p<0.05).
In plain wordsIn 6 healthy volunteers, hexarelin given into a vein raised cortisol release compared with saline.
Peptide
Hexarelin
Outcome
IncreaseCortisol secretion after hexarelin
Study
n = 6
Comparator
Saline
Outcome group
Stress hormones · Endocrine and hormones
Studied dose
1.0 microg/kg · intravenousAs given in this study (human).
Source sentences
Summary
As expected, both ghrelin and hexarelin stimulated GH, PRL, ACTH and cortisol secretion (p<0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
We studied the effects of CST-8 (2.0 microg/kg i.v. as a bolus or 2.0 microg/kg/h i.v. as infusion) on both spontaneous and ghrelin- or hexarelin- (1.0 microg/kg i.v. as bolus) stimulated GH, PRL, ACTH and cortisol secretion in 6 normal volunteers.
Report a problemFND-1806166304

Studies that did not test the peptide alone4

In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Hexarelin.

05HumanNot a test of Hexarelin aloneNon-randomized trialEfficacy outcome
In 6 normal volunteers, CST-8 given as bolus or infusion did not change hexarelin-stimulated GH secretion.
In plain wordsIn 6 healthy volunteers, the compound CST-8 did not change the growth hormone release caused by hexarelin.
Peptide
Hexarelin
Outcome
No significant changeHexarelin-stimulated GH secretion with CST-8
Study
n = 6
Comparator
Hexarelin with saline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
CST-8, administered either as bolus or as continuous infusion, did not modify both spontaneous and ghrelin- or hexarelin-stimulated GH, PRL, ACTH and cortisol secretion.
1 context sentence(design, population, supporting numbers)
Summary · context
We studied the effects of CST-8 (2.0 microg/kg i.v. as a bolus or 2.0 microg/kg/h i.v. as infusion) on both spontaneous and ghrelin- or hexarelin- (1.0 microg/kg i.v. as bolus) stimulated GH, PRL, ACTH and cortisol secretion in 6 normal volunteers.
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-1806166305
06HumanNot a test of Hexarelin aloneNon-randomized trialEfficacy outcome
In 6 normal volunteers, CST-8 given as bolus or infusion did not change hexarelin-stimulated PRL secretion.
In plain wordsIn 6 healthy volunteers, the compound CST-8 did not change the prolactin release caused by hexarelin.
Peptide
Hexarelin
Outcome
No significant changeHexarelin-stimulated PRL secretion with CST-8
Study
n = 6
Comparator
Hexarelin with saline
Outcome group
Pituitary hormones · Endocrine and hormones
Source sentences
Summary
CST-8, administered either as bolus or as continuous infusion, did not modify both spontaneous and ghrelin- or hexarelin-stimulated GH, PRL, ACTH and cortisol secretion.
1 context sentence(design, population, supporting numbers)
Summary · context
We studied the effects of CST-8 (2.0 microg/kg i.v. as a bolus or 2.0 microg/kg/h i.v. as infusion) on both spontaneous and ghrelin- or hexarelin- (1.0 microg/kg i.v. as bolus) stimulated GH, PRL, ACTH and cortisol secretion in 6 normal volunteers.
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-1806166306
07HumanNot a test of Hexarelin aloneNon-randomized trialEfficacy outcome
In 6 normal volunteers, CST-8 given as bolus or infusion did not change hexarelin-stimulated ACTH secretion.
In plain wordsIn 6 healthy volunteers, the compound CST-8 did not change the ACTH release caused by hexarelin.
Peptide
Hexarelin
Outcome
No significant changeHexarelin-stimulated ACTH secretion with CST-8
Study
n = 6
Comparator
Hexarelin with saline
Outcome group
Stress hormones · Endocrine and hormones
Source sentences
Summary
CST-8, administered either as bolus or as continuous infusion, did not modify both spontaneous and ghrelin- or hexarelin-stimulated GH, PRL, ACTH and cortisol secretion.
1 context sentence(design, population, supporting numbers)
Summary · context
We studied the effects of CST-8 (2.0 microg/kg i.v. as a bolus or 2.0 microg/kg/h i.v. as infusion) on both spontaneous and ghrelin- or hexarelin- (1.0 microg/kg i.v. as bolus) stimulated GH, PRL, ACTH and cortisol secretion in 6 normal volunteers.
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-1806166307
08HumanNot a test of Hexarelin aloneNon-randomized trialEfficacy outcome
In 6 normal volunteers, CST-8 given as bolus or infusion did not change hexarelin-stimulated cortisol secretion.
In plain wordsIn 6 healthy volunteers, the compound CST-8 did not change the cortisol release caused by hexarelin.
Peptide
Hexarelin
Outcome
No significant changeHexarelin-stimulated cortisol secretion with CST-8
Study
n = 6
Comparator
Hexarelin with saline
Outcome group
Stress hormones · Endocrine and hormones
Source sentences
Summary
CST-8, administered either as bolus or as continuous infusion, did not modify both spontaneous and ghrelin- or hexarelin-stimulated GH, PRL, ACTH and cortisol secretion.
1 context sentence(design, population, supporting numbers)
Summary · context
We studied the effects of CST-8 (2.0 microg/kg i.v. as a bolus or 2.0 microg/kg/h i.v. as infusion) on both spontaneous and ghrelin- or hexarelin- (1.0 microg/kg i.v. as bolus) stimulated GH, PRL, ACTH and cortisol secretion in 6 normal volunteers.
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-1806166308

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.